Business Context and Reporting Period
The supplied filing is Aileron Therapeutics, Inc.’s Form 10-Q for the quarter ended June 30, 2022, not Rein Therapeutics, Inc. The company is a clinical-stage oncology biotechnology company developing ALRN-6924, an MDM2/MDMX dual inhibitor intended to protect healthy cells from chemotherapy in patients with p53-mutated cancers. The financial statements are unaudited and cover the three and six months ended June 30, 2022, with comparable 2021 periods.
Aileron reported no product revenue and has not commercialized a product candidate. Its principal program was a Phase 1b breast cancer trial; in June 2022, it announced that it would stop further enrollment in its Phase 1b NSCLC trial based on interim data from the first 20 patients.
Key Financial Metrics
| Metric | Three Months Ended June 30 | Six Months Ended June 30 |
|---|---|---|
| Revenue | $0 in 2022 and 2021 | $0 in 2022 and 2021 |
| Research and development expense | $5.4 million vs. $3.9 million | $11.3 million vs. $8.2 million |
| General and administrative expense | $2.6 million vs. $2.2 million | $5.1 million vs. $4.8 million |
| Total operating expenses | $8.0 million vs. $6.0 million | $16.5 million vs. $13.0 million |
| Net loss | $8.0 million, or $0.09 per share, vs. $5.7 million, or $0.06 | $16.4 million, or $0.18 per share, vs. $12.7 million, or $0.15 |
| Cash used in operating activities | Not separately presented | $13.5 million vs. $10.2 million |
Because revenue was zero, conventional revenue or net profit margins are not meaningful. The company had an operating loss equal to its operating expenses and continued to report substantial losses.
- Cash and cash equivalents were $7.6 million at June 30, 2022, compared with $3.6 million at December 31, 2021.
- Short-term investments were $24.8 million, down from $42.3 million at year-end 2021.
- Cash, cash equivalents and investments totaled $32.4 million at June 30, 2022, compared with $45.9 million at December 31, 2021.
- Total assets were $33.8 million and stockholders’ equity was $28.6 million.
- Total liabilities were $5.2 million. The filing shows no outstanding borrowings; liabilities principally comprised accounts payable, accrued expenses and operating lease obligations.
- Accumulated deficit was $261.9 million.
- Stock-based compensation expense was $1.2 million for the first six months of 2022.
Material Changes Versus the Prior Comparable Period
- Second-quarter research and development expense increased $1.6 million, primarily due to higher breast cancer trial spending, additional NSCLC trial spending and increased manufacturing costs for ALRN-6924.
- Six-month research and development expense increased $3.2 million, principally from $1.6 million of additional breast cancer trial spending and $1.3 million of higher manufacturing costs.
- General and administrative expense increased $0.5 million in the second quarter and $0.3 million for the first six months, primarily because of higher professional services fees.
- Six-month operating cash use increased by $3.2 million year over year.
- Investing activities provided $17.5 million in the first six months of 2022, primarily reflecting $29.6 million of investment maturities or sales, partially offset by $12.1 million of investment purchases. In 2021, investing activities used $42.3 million.
- There was no financing cash inflow in the first six months of 2022, compared with $55.6 million from common-stock issuances in the 2021 period.
- The company increased its common shares outstanding modestly to 90.8 million at June 30, 2022 from 90.6 million at December 31, 2021. It also had 12.9 million warrants and 11.1 million stock options outstanding, which were excluded from diluted loss per share because they were antidilutive.
Guidance, Outlook, Risks and Unusual Items
- Management stated that $32.4 million of cash, cash equivalents and investments at June 30, 2022 was expected to fund operating expenses through the first quarter of 2024 under its current operating plan and cash-preservation measures.
- The company expects continuing operating losses and substantial additional funding needs. It may seek equity financing, debt financing, collaborations, licensing arrangements or other strategic transactions.
- Management acknowledged that available resources will not fund all planned development or commercialization activities for ALRN-6924 and that funding assumptions could prove incorrect.
- The breast cancer Phase 1b trial was modified following the NSCLC interim analysis, including changes to the endpoint, chemotherapy regimen and dosing strategy. The company planned a topline readout for 20 patients in the third quarter of 2023, subject to successful trial execution.
- Clinical development remains subject to trial-design uncertainty, patient recruitment challenges, regulatory requirements, manufacturing and supply risks, and potential COVID-19-related disruptions.
- The company had not regained compliance with Nasdaq’s $1.00 minimum bid-price requirement as of the filing date. Nasdaq granted an additional compliance period through December 5, 2022. Stockholders approved authority for a potential 1-for-5 to 1-for-25 reverse stock split.
- The company stated that failure of the breast cancer trial could lead to discontinuation of ALRN-6924 development. If financing is unavailable and trial results are unfavorable, the company indicated it could consider strategic alternatives, dissolution or bankruptcy protection.
- Potential milestone obligations under the Harvard/Dana-Farber and Umicore license agreements totaled up to $7.7 million per licensed therapeutic product and $6.4 million per licensed product, respectively, but no milestone liabilities were recorded because triggering events were not considered probable.
- No material legal proceedings were reported, and management concluded that disclosure controls and procedures were effective as of June 30, 2022.
Most Important Facts to Verify
- Confirm the issuer identity: the supplied filing is for Aileron Therapeutics, Inc., whereas the request identifies Rein Therapeutics, Inc.
- Verify subsequent developments concerning the NSCLC trial, the breast cancer trial, ALRN-6924, and the planned 2023 topline readout.
- Verify actual cash consumption and financing activity after June 30, 2022 against management’s first-quarter 2024 runway estimate.
- Check whether Aileron regained Nasdaq minimum bid-price compliance or completed a reverse stock split by the December 5, 2022 deadline.
- Review subsequent equity issuances, warrant or option dilution, collaborations, licensing transactions and any changes to the company’s clinical strategy.
- Assess whether COVID-19, enrollment, manufacturing, regulatory or clinical efficacy issues caused additional delays or increased costs.